Longevity - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Strategies for reducing excess body fat... - Jill Brook, MA (2021 Conference) (LDN, low dose naltrexone)

Crohn’s - Pamela Smith, MD, MS (2021 Conference) (LDN, low dose naltrexone)

Dr. Pamela Smith discusses Crohn’s, an autoimmune disease, from both a conventional and personalized medicine approach. Siting research and her own clinical experience, Dr. Smith discusses traditional and complementary treatment, dietary and nutritional therapies, as well as the use of Low Dose Naltrexone in treating Crohn’s Disease.

Cancer Case Studies - Akbar Khan, MD (2021 Conference) (LDN, low dose naltrexone)

Cancer is a systemic disease. This presentation is on using low dose naltrexone (LDN) as a cancer treatment, looking at several case reports, diagnostic tests, and various therapies. Cases include breast cancer, nodular melanoma, and adenocarcinoma with lymphovascular invasion in a colonic polyp

Case Reports of Cancer Therapies - Akbar Khan, MD (2021 Conference) (LDN, low dose naltrexone)

Dr. Khan believes in integrative care, combining allopathic and naturopathic therapies. They treat all types of cancer and people of all ages, with a focus on non-toxic therapy, and quality of life.

Opiate Receptor Drugs – To Cycle or Not to Cycle Dosing? - Paul Anderson, NMD (2021 Conference) (LDN, low dose naltrexone)

Mold toxicity - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)

The role of immune modulation in cancer - Professor Angus Dalgleish (2021 Conference) (LDN, low dose naltrexone)

History, Pharmacology and Mechanism - Stephen Dickson, BSC (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)

LDN Research Trust 2021 Conference - Friday Morning

Angus Dalgleish, MD - The Role of Non-Cytotoxic Drugs in the Management of Cancer (2017 Conference) (LDN, low dose naltrexone)